Lilly, FDA clash over retatrutide

Eli Lilly’s dispute with the U.S. Food and Drug Administration over retatrutide is not about whether the obesity drug works. It is about what bucket the drug belongs in before approval. BioSpace reported on August 5 that the fight over whether retatrutide is a biologic is reaching a decision point as Lilly moves toward a U.S. submission. (biospace.com) Lilly has already told investors it plans to file retatrutide as a Biologics License Application, or BLA, in the first quarter of 2027. (investor.lilly.com) The case is live in the U.S. District Court for the Southern District of Indiana, where Lilly sued after FDA denied its request to designate retatrutide as a biological product. The court order says the dispute turns on how FDA applies the statutory and regulatory definition of a “protein” under the Public Health Service Act. (investor.lilly.com) ### Why is Lilly arguing that retatrutide is a biologic? Retatrutide is a once-weekly, investigational triple hormone receptor agonist that Lilly is developing for obesity and related conditions. Lilly has publicly said it plans to submit a BLA, not a New Drug Application, after completing the chemistry, manufacturing and controls package required for that pathway. (biospace.com) The Indiana court order says Lilly brought the case under the Administrative Procedure Act after FDA refused to classify retatrutide as a biologic. The order also lays out FDA’s definition of a protein as “any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size,” which is the core legal standard in the dispute. (ecf.insd.uscourts.gov) ### What exactly is the FDA disagreeing with? The FDA’s position, as described in the court order, is tied to how the agency interprets “alpha amino acid polymer” in the biologics statute and rule. That matters because retatrutide is a peptide-based medicine, and the classification question appears to hinge on whether its structure fits FDA’s protein definition for biologic regulation. (investor.lilly.com) BioSpace reported that the clash has sharpened as Lilly nears submission. The publication said the classification decision affects the review pathway and the evidence package the company must present to regulators. ### Why does the filing pathway matter so much? (ecf.insd.uscourts.gov) A BLA and an NDA do not run through the same statutory framework. The court order notes that biological products are licensed under the Public Health Service Act, while conventional drugs are regulated through the Federal Food, Drug, and Cosmetic Act. That distinction can change what manufacturing information is required, how the product is reviewed and what exclusivity rules may later apply. (ecf.insd.uscourts.gov) Lilly has already aligned its public timeline with the biologics route by saying the retatrutide filing will be a BLA in Q1 2027. ### Is this slowing the drug down? (biospace.com) Lilly’s public guidance still points to a first-quarter 2027 U.S. submission. On July 23, the company said positive Phase 3 data from TRIUMPH-2 and TRIUMPH-3 added to a completed clinical package for obesity-related registrations, and on August 5 it repeated that the plan is a BLA in the first quarter of 2027. (ecf.insd.uscourts.gov) Retatrutide is not approved in the United States today. Lilly’s medical information page says the drug is investigational and cannot be legally sold or marketed for human use. ### What should readers watch next? The next milestone is the first-quarter 2027 submission Lilly has already put on the record. (investor.lilly.com) Before then, the key document trail is likely to come from the Southern District of Indiana case, where the court is handling Lilly’s challenge to FDA’s refusal to designate retatrutide as a biological product. (medical.lilly.com)